NICE recommends Humira (adalimumab) to treat hidradenitis suppurativa- AbbVie
The National Institute for Health and Care Excellence (NICE) recommended the use of Humira (adalimumab) from AbbVie for the treatment of moderate to severe hidradenitis suppurativa (HS, also known as acne inversa), a skin condition, where patients have an inadequate response to conventional therapies such as antibiotics and steroids. The treatment should be assessed after twelve weeks for evidence of a response.
An estimated 977,900 individuals in the UK suffer from the condition. Adalimumab is the first treatment to obtain a licence for active moderate to severe HS and can reduce the number of total inflammatory nodules and abscesses by at least 50%, as well as reduce skin pain by a third.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.